According to Xu et al, roughly half of mesotheliomas display a pyrimidine-high phenotype driven by NF2 deficiency, high CAD/DHODH expression, and the poorest prognosis, most likely the population to benefit the most from targeting de novo pyrimidine synthesis. The gene discussed is NF2; the disease is mesothelioma.